$38.50
+4.05%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$37.81
From 52W high+0.00%
Volume4.78M
Market cap$23.67B
P/E (TTM)30.1x
P/S (TTM)5.7x
Div yield—
Key dataOct 19, 2026
Open
$37.81
From 52W high
+0.00%
Volume
4.78M
Market cap
$23.67B
ValuationView details →
P/E (Fwd)
25.7x
EV/EBITDA
22.5x
P/E (TTM)
30.1x
RSI (14)
64.1
MomentumView details →
1D Return
+4.05%
YTD Return
+25.49%
SummaryUpdated Jun 1, 2026
Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company went public in 2009 and has established itself as a leading developer of innovative antibody therapeutics for cancer treatment. Genmab has evolved from a research-focused biotech startup into a commercially successful company with multiple approved products and a robust pipeline of experimental treatments. The company operates through strategic partnerships with major pharmaceutical companies while also developing and commercializing its own proprietary medicines.
Similar companies
Latest newsMore news →
GENMAB A/S announced that worldwide third-quarter 2026 net trade sales of DARZALEX, as reported by JOHNSON & JOHNSON, were USD 4,239 million, including USD 2,528 million in the United States and USD 1,711 million in the rest of the world.7d agoGenmab (GMAB) shares jumped 10.7% in the previous trading session on above-average trading volume.14d agoGenmab shares continued to rise in Copenhagen, gaining as much as 6%.14d ago